Cargando…

Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema

BACKGROUND/AIMS: The RELIGHT clinical trial used an individualised treatment regimen of ranibizumab to treat diabetic macular oedema (DMO). We report findings from two patient-reported outcome instruments. METHODS: The National Eye Institute Visual Function Questionnaire (NEI-VFQ) was administered b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakravarthy, Usha, Pearce, Ian, Banerjee, Sanjiv, Burton, Benjamin J L, Downey, Louise, Gale, Richard, Patel, Jignesh, Patra, Sudeshna, Sivaprasad, Sobha, Stevenson, Michael, Lupton, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528749/ https://www.ncbi.nlm.nih.gov/pubmed/31179389 http://dx.doi.org/10.1136/bmjophth-2018-000226

Ejemplares similares

Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
por: Talks, S. James, et al.
Publicado: (2019)

Indicators of Visual Prognosis in Diabetic Macular Oedema
por: Sen, Sagnik, et al.
Publicado: (2021)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin, Philip, et al.
Publicado: (2016)

Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration
por: Gohil, Rishma, et al.
Publicado: (2015)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases
por: Vemala, Roopa, et al.
Publicado: (2010)

Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting
por: Gohil, Rishma, et al.
Publicado: (2016)

Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
por: Wong, Yun, et al.
Publicado: (2016)

Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema
por: Abdel-Hay, Ahmed, et al.
Publicado: (2018)

Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group
por: Amoaku, Winfried M., et al.
Publicado: (2020)

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS)
por: Stefanickova, Jana, et al.
Publicado: (2018)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration: Early Detection of Neovascular Age-Related Macular Degeneration Study
por: Sivaprasad, Sobha, et al.
Publicado: (2021)

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
por: Hykin, Philip, et al.
Publicado: (2019)

Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
por: Ziemssen, Focke, et al.
Publicado: (2017)

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
por: Prünte, Christian, et al.
Publicado: (2016)

Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema
por: Morse, Lawrence, et al.
Publicado: (2019)

A method of single reference image based scene relighting
por: Jin, Xin, et al.
Publicado: (2018)

Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4)
por: Sivaprasad, Sobha, et al.
Publicado: (2013)

Correction: Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4)
por: Sivaprasad, Sobha, et al.
Publicado: (2013)

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review
por: Ford, John A, et al.
Publicado: (2012)

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2021)

Two-year visual and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)
por: Sakamoto, Taiji, et al.
Publicado: (2022)

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
por: Sadda, Srinivas R., et al.
Publicado: (2019)

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)

Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study
por: Amoaku, Winfried M., et al.
Publicado: (2015)

Factors Affecting Reading Speed in Patients with Diabetic Macular Edema Treated with Laser Photocoagulation
por: Pearce, Elizabeth, et al.
Publicado: (2014)

The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy
por: Nicholson, Luke, et al.
Publicado: (2021)

Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era
por: Downey, Louise, et al.
Publicado: (2021)

Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab
por: Ebneter, Andreas, et al.
Publicado: (2016)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial
por: Lois, Noemi, et al.
Publicado: (2019)

Evaluation of standard-of-care intravitreal aflibercept treatment practices in patients with diabetic macular oedema in the UK: DRAKO study outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)

Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sivaprasad, Sobha
Publicado: (2008)

Evaluation of care with intravitreal aflibercept treatment for UK patients with diabetic macular oedema: DRAKO study 24-month real-world outcomes
por: Sivaprasad, Sobha, et al.
Publicado: (2023)

Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial
por: Mitchell, Paul, et al.
Publicado: (2012)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema
por: Podkowinski, Dominika, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_spcmpkgln2460rhk4be2ojcls0